Monogram Orthopaedics Announces Acquisition by Zimmer Biomet

Monogram Orthopaedics Inc ( (MGRM) ) has issued an announcement.

On July 28, 2025, Monogram Technologies Inc. provided its stockholders with FAQs regarding its proposed acquisition by Zimmer Biomet Holdings, Inc., initially announced on July 14, 2025. The acquisition will result in each Monogram common share being converted into cash and a Contingent Value Right (CVR), with the merger expected to close in the second half of 2025, subject to regulatory and stockholder approval. Monogram shares will be delisted from Nasdaq post-acquisition, and the company will become a wholly-owned subsidiary of Zimmer Biomet.

The most recent analyst rating on (MGRM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Monogram Orthopaedics Inc stock, see the MGRM Stock Forecast page.

Spark’s Take on MGRM Stock

According to Spark, TipRanks’ AI Analyst, MGRM is a Neutral.

Monogram Orthopaedics Inc. shows promise due to significant technological advancements and recent regulatory clearances, which are key drivers for potential growth. However, financial instability, regulatory uncertainties, and ongoing profitability challenges weigh heavily on the overall score. The stock’s upward momentum is a positive indicator, but valuation metrics remain weak due to negative earnings and lack of dividends.

To see Spark’s full report on MGRM stock, click here.

More about Monogram Orthopaedics Inc

Average Trading Volume: 339,098

Technical Sentiment Signal: Buy

For an in-depth examination of MGRM stock, go to TipRanks’ Overview page.